Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074880 | 0.88 | PTGES (0.49) | MAPTHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL1490598 | 0.88 | PTGES (0.49) | MAPTHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL28468025 | 0.83 | EGFR (0.42) | MAPTHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL2246946 | 0.82 | TDP1 (0.45) | MAPTHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL404980 | 0.82 | TSHR (0.45) | MAPTHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL2143638 | 0.82 | MEN1 (0.40) | MAPTHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL1025814 | 0.82 | MAPT (0.48) | MAPTHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL358123 | 0.82 | EGFR (0.42) | MAPTHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL1557518 | 0.82 | LMNA (0.41) | MAPTHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL28028333 | 0.82 | MEN1 (0.40) | MAPTHTTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015145369-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, INTERMEDIATES AND POLYMORPHS THEREOF | Piramal Enterprises Limited (IN) | 2015-10-01 | — | — | WO | claimed |
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4522616-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119546607-A | LRRK2 inhibitors | 因特来治疗公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119403801-A | LRRK2 inhibitors | 因特来治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| US-12060350-B2 | Therapeutic compounds and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-08-13 | — | — | US | disclosed |
| CN-117800964-A | PI3K/m-TOR inhibitor and application thereof | 四川大学 | 2024-04-02 | — | — | CN | disclosed |
| CN-117756799-A | Compound and application thereof in preparation of ATM kinase inhibitor | 四川大学华西医院 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | CAPRARO HANS-GEORG | 2007-09-13 | — | — | US | disclosed |
| WO-2007075468-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| CN-1902200-A | 1h-imidazoquinoline derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2007-01-24 | — | — | CN | disclosed |
| CN-1882586-A | 1H-imidazo[4,5-C]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2006-12-20 | — | — | CN | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006091394-A2 | SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1689747-A1 | 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| EP-1687305-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054237-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | MAPT 2704/4885HTT 683/4885MEN1 1016/4885 |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | ABL1, PRKCA, PRKCQ | MAPT 1440/4885HTT 1568/4885MEN1 2099/4885 |
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | MAPT 14/4885HTT 259/4885MEN1 2410/4885 |
| US-12060350-B2 | Therapeutic compounds and methods of use thereof | MYD88, CD47, ARG1 | MAPT 4293/4885HTT 3323/4885MEN1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.